Literature DB >> 23319395

Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.

Traian Dumitrascu1, Dragos Chirita, Mihnea Ionescu, Irinel Popescu.   

Abstract

INTRODUCTION: Resection for hilar cholangiocarcinoma is the single hope for long-term survival.
METHODS: Ninety patients underwent curative intent surgery for hilar cholangiocarcinoma between 1996 and 2012. The potential prognostic factors were assessed by univariate (Kaplan-Meier curves and log-rank test) and multivariate analyses (Cox proportional hazards model).
RESULTS: The median overall and disease-free survivals were 26 and 17 months, respectively. The multivariate analysis identified R0 resection (HR = 0.03, 95 % CI 0-0.19, p < 0.001), caudate lobe invasion (HR = 6.33, 95 % CI 1.31-30.46, p = 0.021), adjuvant gemcitabine-based chemotherapy (HR = 0.38, 95 % CI 0.15-0.94, p = 0.037), and the neutrophil-to-lymphocyte ratio (HR = 0.78, 95 % CI 0.62-0.98, p = 0.036) as independent prognostic factors for disease-free survival. The independent prognostic factors for overall survival were R0 resection (HR = 0.03, 95 % CI 0-0.22, p < 0.001), caudate lobe invasion (HR = 11.75, 95 % CI 1.65-83.33, p = 0.014), and adjuvant gemcitabine-based chemotherapy (HR = 0.19, 95 % CI 0.06-0.56, p = 0.003).
CONCLUSIONS: The negative resection margin represents the most important prognostic factor. Adjuvant gemcitabine-based chemotherapy appears to benefit survival. The neutrophil-to-lymphocyte ratio may potentially be used to stratify patients for future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319395     DOI: 10.1007/s11605-013-2144-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  58 in total

1.  Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.

Authors:  A Kobayashi; S Miwa; T Nakata; S Miyagawa
Journal:  Br J Surg       Date:  2010-01       Impact factor: 6.939

2.  Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

Authors:  G Garcea; N Ladwa; C P Neal; M S Metcalfe; A R Dennison; D P Berry
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).

Authors:  Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-01-14       Impact factor: 3.982

4.  One hundred consecutive hepatobiliary resections for biliary hilar malignancy: preoperative blood donation, blood loss, transfusion, and outcome.

Authors:  Masato Nagino; Junichi Kamiya; Toshiyuki Arai; Hideki Nishio; Tomoki Ebata; Yuji Nimura
Journal:  Surgery       Date:  2005-02       Impact factor: 3.982

5.  Extent of liver resection for hilar cholangiocarcinoma (Klatskin tumor): how much is enough?

Authors:  Thomas M van Gulik; Anthony T Ruys; Oliver R C Busch; Erik A J Rauws; Dirk J Gouma
Journal:  Dig Surg       Date:  2011-04-29       Impact factor: 2.588

6.  Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival.

Authors:  Q Cheng; X Luo; B Zhang; X Jiang; B Yi; M Wu
Journal:  Eur J Surg Oncol       Date:  2006-11-07       Impact factor: 4.424

7.  Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor).

Authors:  Sander Dinant; Michael F Gerhards; E A J Rauws; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  Ann Surg Oncol       Date:  2006-04-14       Impact factor: 5.344

8.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroaki Nakamura; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

10.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

Authors:  M J Proctor; D C McMillan; D S Morrison; C D Fletcher; P G Horgan; S J Clarke
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

View more
  33 in total

1.  The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Authors:  Akira Iwaku; Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Hirokazu Nishino; Masato Matsushima; Hisao Tajiri
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

2.  Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors.

Authors:  Mohamed Abd ElWahab; Ayman El Nakeeb; Ehab El Hanafy; Ahmad M Sultan; Ahmed Elghawalby; Waleed Askr; Mahmoud Ali; Mohamed Abd El Gawad; Tarek Salah
Journal:  World J Gastrointest Surg       Date:  2016-06-27

Review 3.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

4.  Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma.

Authors:  Masataka Okuno; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Masato Nagino
Journal:  J Gastroenterol       Date:  2015-07-18       Impact factor: 7.527

Review 5.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

6.  Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-08-03       Impact factor: 3.452

Review 7.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

8.  Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.

Authors:  Hai-Jie Hu; Hui Mao; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

9.  Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.

Authors:  Bas Groot Koerkamp; Jimme K Wiggers; Peter J Allen; Marc G Besselink; Leslie H Blumgart; Olivier R C Busch; Robert J Coelen; Michael I D'Angelica; Ronald P DeMatteo; Dirk J Gouma; T Peter Kingham; William R Jarnagin; Thomas M van Gulik
Journal:  J Am Coll Surg       Date:  2015-09-15       Impact factor: 6.113

Review 10.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.